AnteoTechAnteoTechAnteoTechAnteoTech
  • Home
  • About
    • MANAGEMENT TEAM
    • BOARD OF DIRECTORS
  • Life Science
    • ANTEOBIND
      • ANTEOBIND PUBLICATIONS
    • PRODUCTS
    • CONTRACT SERVICES
    • CASE STUDIES
    • WEBINARS
  • Energy
    • WEBINARS
  • COVID-19
  • Investors
    • ASX ANNOUNCEMENTS
    • CORPORATE GOVERNANCE & COMPANY POLICY
    • VIEW ON ASX
  • Contact

ASX Announcements

Unlocking Lateral Flow Conjugation to Develop Point of Care Solutions

Filter Categories
Filter - All
2021 Announcements
2020 Announcements
2019 Announcements
  • EuGeni Test Strip Manufacturing Strategy
    May 23, 2021
    AnteoTech Ltd is pleased to provide an overview of the lateral flow rapid test manufacturing strateg...
  • AnteoTech raises $8.0m in strongly supported SPP
    May 20, 2021
    AnteoTech had received applications totalling $37.1 million by the close of the SPP on 18 May 2021. ...
  • Update - AnteoTech signs manufacturing contract with Operon
    May 16, 2021
    AnteoTech Ltd is pleased to announce that it has finalised and signed a manufacturing contract for i...
  • Section 708A Notice and Appendix 2A
    May 5, 2021
    20210505 Section 708A Notice and Appendix 2A
  • Share Purchase Plan Cleansing Notice
    May 4, 2021
    20210504 Share Purchase Plan Cleansing Notice
  • Share Purchase Plan Offer Booklet
    May 4, 2021
    20210504 Share Purchase Plan Offer Booklet
  • Appendix 4C - Quarterly
    April 30, 2021
    20210430 Appendix 4C - Quarterly Cashflow Report
  • Quarterly Activities Report
    April 30, 2021
    20210430 Quarterly Activities Report
  • Appendix 2A
    April 29, 2021
    20210429 Appendix 2A
  • Proposed issue of Securities - ADO
    April 28, 2021
    20210428 Proposed issue of Securities - ADO
  • Investor Presentation
    April 28, 2021
    20210428 Investor Presentation
  • AnteoTech secures funding to support launch and pipeline
    April 28, 2021
    202010428 AnteoTech secures funding to support launch and pipeline
  • Trading Halt
    April 25, 2021
    AnteoTech Ltd requests an immediate trading halt in respect of its quoted shares and options.2021042...
  • Energy Collaborator Program Creates Commercial Pathway
    April 25, 2021
    AnteoTech Ltd is pleased to report that evaluation work conducted by AnteoTech’s Collaborators, focu...
  • Invitation to Register for EuGeni Launch Webinar
    April 22, 2021
    The Board and Chief Executive Officer of Brisbane-based biotech company, AnteoTech Ltd invite shareh...
  • Test Platform and COVID-19 Test receive CE Mark approval
    April 11, 2021
    AnteoTech Ltd is pleased to advise that it has received Conformitè Europëenne (CE) Mark registration...
  • AnteoTech Joins $130M Future Battery Industries CRC
    April 8, 2021
    AnteoTech is pleased to advise that it has executed a Project Participation Agreement with the Futur...
  • AnteoTech appoints Chief Financial Officer
    March 31, 2021
    AnteoTech Ltd is pleased to announce the appointment of Ms Gail Jukes as Chief Financial Officer (CF...
  • Updated Company Presentation
    March 25, 2021
    AnteoTech Ltd is pleased to provide shareholders and the market with the updated “Company Presentati...
  • InvestorStream Interview - Presentation
    March 22, 2021
    AnteoTech Ltd is pleased to provide a copy of the presentation by CEO Derek Thomson for the Investor...
  • AnteoTech COVID-19 Antigen Rapid Test Clinical Study Results
    March 21, 2021
    Brisbane based nanotechnology company AnteoTech Ltd is pleased to report the outcome of the COVID-19...
  • Appendix 2A
    March 3, 2021
    20210303 Appendix 2A
  • Life Science Update
    March 1, 2021
    20210301 Life Science Update
  • Half Year Report - Appendix 4D and Interim Financial Report
    February 26, 2021
    Half-Year Report For the half-year ended 31 December 2020 This half-year report is provided by A...
  • AnteoTech Customer Ellume Secure US Contract
    February 3, 2021
    Brisbane based nanotechnology company AnteoTech Ltd notes our customer Ellume has made an announceme...
  • Quarterly Activities Report
    January 29, 2021
    Activities for the Quarter in the Life Sciences Division focused on the development of the COVID-191...
  • Appendix 4C - Quarterly
    January 29, 2021
    20210129 Appendic 4C - Quarterly
  • Up to $1.4m in Qld Grant for COVID-19 test development
    January 20, 2021
    Brisbane based AnteoTech Ltd is pleased to announce that it has been awarded up to $1.4 million towa...
  • AnteoTech Progresses COVID-19 Test Toward Market Launch
    December 23, 2020
    AnteoTech Ltd is pleased to provide a brief update on the COVID-19 Antigen Rapid Test (ART) developm...
  • Change of Director's Interest Notice
    December 9, 2020
    20201209 Change of Director's Interest Notice
  • Section 708A Notice and Appendix 2A
    December 9, 2020
    20201209 Section 708A Notice and Appendix 2A
  • $3.9M Options Exercise Complete
    December 9, 2020
    AnteoTech Ltd  is pleased to advise that it has now received the full $3.9 million from the exercise...
  • Appendix 2A
    December 2, 2020
    20201203 Appendix 2A
  • Change of Director's Interest Notice
    December 2, 2020
    20201203 Change of Director's Interest Notice
  • Appendix 2A
    December 1, 2020
    20201201 Appendix 2A
  • $1.19 million R&D Tax Incentive Refund Received
    November 26, 2020
    AnteoTech Ltd is pleased to advise that it has received a cash refund of $1,195,634 under the Federa...
  • AnteoTech freeze design of COVID19 test
    November 25, 2020
    AnteoTech Ltd  is pleased to announce that all development processes and internal testing procedures...
  • Change of Director's Interest Notice
    November 23, 2020
    20201123 Change of Director's Interest Notice
  • Appendix 2A
    November 23, 2020
    20201123 Appendix 2A
  • Change of Director's Interest Notice
    November 16, 2020
    20201116 Change of Director's Interest Notice x4
  • Appendix 2A
    November 16, 2020
    20201116 Appendix 2A
  • Results of AGM
    November 12, 2020
    20201112 Results of AGM
  • Post AGM Update - Presentation
    November 12, 2020
    20201112 Post AGM Update - Presentation
  • AGM - Chairman's Address
    November 11, 2020
    20201112 AGM Chairmans Address
  • Appendix 2A
    November 10, 2020
    20201110 Appendix 2A
  • Post AGM Update
    November 10, 2020
    20201110 Post AGM Update
  • Appendix 2A
    November 2, 2020
    20201102 Appendix 2A
  • Appendix 4C - quarterly
    October 30, 2020
    20201030 Appendix 4C - quarterly
  • Quarterly Activities Report
    October 30, 2020
    20201030 Quarterly Activities Report
  • Investor Briefing - Energy
    October 28, 2020
    20201028 Investor Briefing - Energy
  • Notice to Quoted ADOO Optionholders
    October 26, 2020
    20201026 Notice to Quoted ADOO Optionholders
  • Appendix 2A
    October 26, 2020
    20201026 Appendix 2A
  • Study Confirms Targeted Sensitivity of COVID-19 Test
    October 21, 2020
    20201021 Study Confirms Targeted Sensitivity of COVID-19 Test
  • Appendix 2A
    October 19, 2020
    20201019 Appendix 2A
  • Proposed issue of Securities - ADO
    October 19, 2020
    20201019 Proposed issue of Securities - ADO
  • Appendix 2A
    October 12, 2020
    20201012 Appendix 2A
  • Notice of Annual General Meeting/Proxy Form
    October 9, 2020
    20201009 Notice of Annual General MeetingProxy Form
  • Investor Briefing
    October 6, 2020
    20201006 Investor Briefing
  • Appendix 2A
    September 28, 2020
    20200928 Appendix 2A
  • Appendix 2A
    September 16, 2020
    20200916 Appendix 2A
  • AnteoTech Achieve ISO-13485 Certification
    September 10, 2020
    20200910 AnteoTech Achieve ISO-13485 Certification
  • AnteoTech COVID-19 Antigen Test Progress Update
    September 9, 2020
    20200909 AnteoTech COVID-19 Antigen Test Progress Update
  • Appendix 2A
    September 2, 2020
    20200902 Appendix 2A
  • Appendix 4G
    August 28, 2020
    2020.08.28 - ADO ASX - ASX App 4G
  • Corporate Governance Statement
    August 28, 2020
    2020.08.28 - ADO ASX - Corp Gov Statement
  • Annual Report to Shareholders
    August 28, 2020
    2020.06.30 - ADO - Annual Report - FINAL
  • AnteoTech Developing Multiplex Test For COVID-19
    July 17, 2020
    AnteoTech develops proof of concept COVID-19/Flu A&B multiplex test platform Tests lever...
  • AnteoTech and Axxin Build Successful Sepsis Multiplex Test
    May 14, 2020
    Sepsis Test
  • Quarterly Cash Flow Report
    April 30, 2020
    Quarterly Cash Flow Report April 20
  • Quarterly Activities Report
    April 30, 2020
    Qurterly Activities Report April 20
  • R&D Refund Received
    April 15, 2020
    R&D Refund Rec'd
  • Response to ASX Query
    April 14, 2020
    Response to ASX April 20
  • Appendix 2A
    April 3, 2020
    Appendix 2A 3:4
  • Change of Directors Interest x 4
    April 3, 2020
    Change Dir. Int x4
  • Appendix 2A
    March 31, 2020
    2A 31:3
  • Rights Issue Raises $2.15 Million
    March 27, 2020
    Rights Issue Closes
  • Heads of Agreement Signed With Merck
    March 9, 2020
    Heads of Agreement Signed With Merck
  • Rights Commence Trading
    March 5, 2020
    Rights Commence Trading
  • Appendix 2A
    March 4, 2020
    Appendix 2A
  • Share and Option Holders Letters
    March 2, 2020
    Share and Option Holders Letter
  • Appendix 3B
    March 2, 2020
    Appendix 3B
  • Rights Issue Prospectus
    March 2, 2020
    Rights Issue Prospectus
  • Rights Issue
    March 2, 2020
    Rights Issue
  • AnteoTech Business Update
    March 2, 2020
    Business Update
  • AnteoTech Granted Key US Patent
    February 27, 2020
    AnteoTech US Patent
  • Half Yearly Report and Accounts
    February 27, 2020
    Half Yearly Accounts
  • Appendix 2A
    February 17, 2020
    2A 17 Feb 20
  • Appendix 2A
    February 10, 2020
    2A 10 Feb 20
  • Quarterly Cashflow Report
    January 30, 2020
    Quarterly Cashflow 30:01:20
  • Quarterly Activities Report
    January 23, 2020
    Quarterly Activities Report 23:01:20
  • Appendix 2A
    January 22, 2020
    Appendix 2A 22:01:20
  • Response to ASX Price Query
    January 13, 2020
    Response to ASX Price Query 13:01:20
  • Appendix 3B
    December 16, 2019
    Appendix 3B 16:12:19
  • Battery Program Update
    December 16, 2019
    Battery Program Update 16:12:20
  • IMRA Contract Additional Information
    November 28, 2019
    IMRA Contrcat Additional Information 28:11:19
  • Response to ASX Aware Query
    November 21, 2019
    Response to ASX Aware Query 21:11:2019
  • AnteoTech signs commercial contract with IMRA
    November 18, 2019
    AnteoTech signs commercial contract 18:11:19
  • Change of Company Name
    November 15, 2019
    Change of Company Name 15:11:19
  • Results of AGM
    November 11, 2019
    Results of AGM 11:11:19
  • AGM Presentation
    November 11, 2019
    AGM Presentation 11:11:19
  • Chairmens Address to Shareholders
    November 11, 2019
    Chairmans Address to Shareholders 11:11:19
  • Appendix 4C - Quarterly
    October 31, 2019
    Appendix 4c Quarterly 31:10:20
  • Quarterly Activities Report
    October 30, 2019
    Quarterly Activities Report 30:10:19
  • Appendix 3B
    October 22, 2019
    Appendix 3b - 22:10:19
  • Notice of Annual General Meeting
    October 8, 2019
    Notice of Annual General Meeting 8:10:19
  • Unmarketable Parcel Share Sale Facility
    October 2, 2019
    Unmarketable Parcel Share 02:10:19
  • Change of Directors Interest Notice
    October 1, 2019
    Change of Directors Interest Notice 01:10:19
  • Appendix 3B
    October 1, 2019
    Appendix 3B 01:10:19
  • Axxin Collaboration
    September 25, 2019
    Axxin Collaboration 25:09:19
  • Material Growth in Point of Care Sector
    September 9, 2019
    Material Growth in Point of Care 09:09:19
  • Appendix 4G
    August 27, 2019
    Appendix 4g 27:08:19
  • Corporate Governance Statement
    August 27, 2019
    Corporate Governance Statement 27:08:19
  • Annual Report to Shareholders
    August 27, 2019
    Annual Report to Shareholders 27:08:19
  • Preliminary Final Report
    August 27, 2019
    Premilimary Final Report 27:08:19
  • Appendix 3B 08/08/19
    August 8, 2019
    Appendix 3b 08:08:19

Quick Links

  • About
  • Life Science
  • Energy
  • Investors

Investors

  • Investor Information
  • Corporate Governance & Company Policy

Contact Us

If you have any general questions about our products or technology, contact customer support on (07) 3219 0085 or email contact@anteotech.com. For all technical support, please email support@anteotech.com.

For all investor-related queries please email investors@anteotech.com.

Copyright © AnteoTech 2021. All rights reserved. AnteoCoat/AnteoBind are trademarks of the AnteoTech group of companies. All other trademarks referenced are owned by their respective companies.
Website by Start Digital
  • Home
  • About
    • MANAGEMENT TEAM
    • BOARD OF DIRECTORS
  • Life Science
    • ANTEOBIND
      • ANTEOBIND PUBLICATIONS
    • PRODUCTS
    • CONTRACT SERVICES
    • CASE STUDIES
    • WEBINARS
  • Energy
    • WEBINARS
  • COVID-19
  • Investors
    • ASX ANNOUNCEMENTS
    • CORPORATE GOVERNANCE & COMPANY POLICY
    • VIEW ON ASX
  • Contact
AnteoTech